Six month repeat cognitive testing to identify people with MCI at greatest AD dementia risk

Systematic review. The authors reviewed the literature using traditional (e.g. PubMed) sources. There is a modest literature on change scores in the context of the AD clinical spectrum, but few investigations have evaluated whether short-term changes may be able to identify a high-risk subgroup of people with MCI. The authors have published a systematic review of this literature (Jutten et al. 2020) and appropriately refer to relevant citations here.Interpretation: Our findings suggest that short-term changes in cognition may be useful as part of a strategy to identify subsets of people with MCI who are at highest risk of conversion. Findings were clearest for memory and language. Domain-specific changes appeared to be independent from other biomarkers used to identify people at highest risk. Domain-specific changes did not appear to be better than changes in global cognition as measured by the MMSE or the CDR-sum of boxes.Future directions: Short-term changes in cognition may be useful to help identify a subgroup of people with MCI at highest risk of conversion to AD dementia. Future work could consider time frames shorter than the 6-month data we had available, better characterizing changes with more than 2 time points, or developing strategies that combine changes in cognition with other biomarkers to identify a subgroup of people with MCI to target for treatment.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2025-12-30
DOI
https://doi.org/10.64898/2025.12.30.25343228
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Six month repeat cognitive testing to identify people with MCI at greatest AD dementia risk

Douglas Tommet, Melissa Lamar, Roos J. Jutten, Dan Mungas et al.
medRxiv
Dementia and Cognitive Impairment Research
article

Six month repeat cognitive testing to identify people with MCI at greatest AD dementia risk

Douglas Tommet, Melissa Lamar, Roos J. Jutten, Dan Mungas, Evan Grandoit, Richard N. Jones, Connie Nakano, Nancy S. Foldi, Phoebe Scollard, Chun Wang, Seo-Eun Choi, the Alzheimer's Disease Neuroimaging Initiative, Laura E Gibbons, Laura Rabin, Paul K Crane, Michael Lee
article en

Abstract

Systematic review. The authors reviewed the literature using traditional (e.g. PubMed) sources. There is a modest literature on change scores in the context of the AD clinical spectrum, but few investigations have evaluated whether short-term changes may be able to identify a high-risk subgroup of people with MCI. The authors have published a systematic review of this literature (Jutten et al. 2020) and appropriately refer to relevant citations here.Interpretation: Our findings suggest that short-term changes in cognition may be useful as part of a strategy to identify subsets of people with MCI who are at highest risk of conversion. Findings were clearest for memory and language. Domain-specific changes appeared to be independent from other biomarkers used to identify people at highest risk. Domain-specific changes did not appear to be better than changes in global cognition as measured by the MMSE or the CDR-sum of boxes.Future directions: Short-term changes in cognition may be useful to help identify a subgroup of people with MCI at highest risk of conversion to AD dementia. Future work could consider time frames shorter than the 6-month data we had available, better characterizing changes with more than 2 time points, or developing strategies that combine changes in cognition with other biomarkers to identify a subgroup of people with MCI to target for treatment.

medRxiv
Queens College, CUNY (US), Northwestern University (US), Rush University Medical Center (US), University of Washington (US), Cornell University (US), Brown University (US), Massachusetts General Hospital (US), MIND Research Institute (US), University of Washington Applied Physics Laboratory (US), Brooklyn College (US), University of California, Davis (US)
U.S. Department of Defense, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Biogen, Meso Scale Diagnostics, Alzheimer's Disease Neuroimaging Initiative, BioClinica, Novartis Pharmaceuticals Corporation, Eisai, H. Lundbeck A/S, IXICO, National Institutes of Health, Genentech, National Institute of General Medical Sciences
Quality Education
Openalex Percentile: Top 31%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.